Read news on biontech with our app.
Read more in the app
BioNTech’s Loss Is Wider Than Expected as Vaccine Sales Hurt
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma | BioNTech
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
Biontech is planning cancer vaccines before 2030
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211